A federal judge has ruled that a qui tam suit on behalf of more than two dozen states, accusing a Johnson & Johnson subsidiary of off-label marketing of HIV/AIDS drugs, can move ahead in pared-down form.
U.S. District Judge Michael Shipp, granting in part and denying in part a summary judgment motion, ruled May 30 that some claims against Janssen Products can proceed.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
